PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Novel drug regimen can improve stem cell transplantation outcomes

Bortezomib (Velcade) reduces GVHD, boosts survival

2013-12-08
(Press-News.org) Contact information: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Novel drug regimen can improve stem cell transplantation outcomes Bortezomib (Velcade) reduces GVHD, boosts survival

NEW ORLEANS— Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.

In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall survival than has been seen historically with such patients receiving standard preventive therapy, the investigators reported at the American Society of Hematology annual meeting.

"This regimen appears to improve not just GVHD prevention but more importantly, overall and relapse-free survival for myeloablative transplant recipients lacking matched sibling donors," said John Koreth, MBBS, DPhil, of Dana-Farber, the lead author and study PI. The senior author is Edwin P. Alyea, III, MD, also of Dana-Farber.

Stem cell transplantation following myeloablation (high-dose chemotherapy to wipe out the patient's bone marrow and immune system) is a curative therapy in advanced or aggressive hematologic malignancies, Koreth said. However, recipients who lack preferred matched sibling donors have worse outcomes, with higher treatment-related mortality and severe GVHD, and poorer survival.

Bortezomib, a proteasome inhibitor drug, is a mainstay of treatment for multiple myeloma. In addition to killing cancer cells, bortezomib dampens some immune responses, suggesting it may have a role in mitigating GVHD, the result of donor immune cells attacking the transplant recipient's normal tissues.

The prospective, single-arm phase 2 trial of a bortezomib-based regimen enrolled 34 patients with hematologic malignancies who received myeloablative stem cell transplants. In addition to standard GVHD prophylaxis medications – tacrolimus and methotrexate - the patients received three doses of bortezomib (on the first, fourth and seventh day after transplant). The treatment was well-tolerated with no patients missing doses because of toxicity.

Historically, recipients of unrelated and mismatched donor transplants have severe acute GVHD rates of 28 percent and 37 percent, respectively, with one-year treatment-related mortality of 36 percent and 45 percent, respectively, and one-year overall survival of 52 percent and 43 percent, respectively.

In patients treated with bortezomib in the new study, the rate of severe acute GVHD at 180 days after transplant was only 12 percent. By two years, only 8.8 percent of patients had died from treatment-related mortality, and 5.9 percent had died from disease relapse. Overall survival at two years was high at 84 percent.

Koreth said that a randomized trial of bortezomib for GVHD prevention is ongoing at Dana-Farber.



INFORMATION:

Additional authors include Haesook Kim, PhD, and Joseph Antin, MD, both of Dana-Farber.

The research was supported by National Cancer Institute grant P01 CA142106 and by Millennium Pharmaceuticals and Otsuka Pharmaceutical Co.



ELSE PRESS RELEASES FROM THIS DATE:

Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease

2013-12-08
Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease In lab studies, CHOP researchers reprogram gene expression, showing proof-of-concept for potential therapy Hematology researchers at The Children's Hospital ...

Survey: Knowledge about HPV vaccine effectiveness lacking

2013-12-08
Survey: Knowledge about HPV vaccine effectiveness lacking ATLANTA — Knowledge about the efficacy of the human papillomavirus (HPV) vaccine in preventing cervical cancer was lacking in the majority of survey respondents for whom the information ...

Certain genetic alterations may explain head and neck cancer survival disparities

2013-12-08
Certain genetic alterations may explain head and neck cancer survival disparities ATLANTA — Certain genetic alterations to the PAX gene family may be responsible for survival disparities seen between African-American and non-Latino white men ...

Genetic mutations and molecular alterations may explain racial differences in head and neck cancers

2013-12-08
Genetic mutations and molecular alterations may explain racial differences in head and neck cancers Study helps explain why 'survival gap' persists for African-Americans A team of scientists at Johns Hopkins and in Texas has identified a handful of genetic mutations ...

Age shouldn't limit access to transplants for MDS, study suggests

2013-12-08
Age shouldn't limit access to transplants for MDS, study suggests NEW ORLEANS— Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according ...

Rare cause of anemia in newborns often overlooked, research suggests

2013-12-08
Rare cause of anemia in newborns often overlooked, research suggests Scientists recommend testing for Pearson syndrome in patients with congenital anemia Some babies diagnosed with and treated for a bone marrow failure disorder, called Diamond Blackfan ...

T cell immunotherapy: Promising results in children and adults with leukemia

2013-12-07
T cell immunotherapy: Promising results in children and adults with leukemia Researchers from The Children's Hospital of Philadelphia and University of Pennsylvania harness engineered T cells to eliminate tumors in blood Nearly 90 percent of ...

High-tech gene-therapy advances offer hope for patients with hard-to-treat blood disorders

2013-12-07
High-tech gene-therapy advances offer hope for patients with hard-to-treat blood disorders (NEW ORLEANS, December 7, 2013) – A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients ...

Advances in stem cell transplantation strategies show promise to improve availability, success

2013-12-07
Advances in stem cell transplantation strategies show promise to improve availability, success (NEW ORLEANS, December 7, 2013) – Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug ...

International gene therapy trial for 'bubble boy' disease shows promising early results

2013-12-07
International gene therapy trial for 'bubble boy' disease shows promising early results 8 of 9 children treated doing well, according to data presented to American Society of Hematology (NEW ORLEANS, December 7, 2013) – Hematopoietic stem cell transplantation ...

LAST 30 PRESS RELEASES:

Canadian health data security is critical in changing political climate

Helping Canada lead in health innovation

Virtual care network for rural and First Nations communities

Dementia takes 3.5 years to diagnose after symptoms begin

Robotic space rovers keep getting stuck. UW engineers have figured out why

New research shows how immigration status can become a death sentence during public health crisis

University of Toronto Engineering researchers develop safer alternative non-stick coating

Good vibrations: Scientists use imaging technology to visualize heat

More ecological diversity means better nutritional resources in Fiji’s agroforests

New global study shows freshwater is disappearing at alarming rates

Scientists create an artificial cell capable of navigating its environment using chemistry alone

A little salt is good for battery health

Deep-sea fish confirmed as a significant source of ocean carbonate

How to keep kids with eating disorders home after hospital stay? Therapy

Sex differences affect efficacy of opioid overdose treatment

Aligning AI with Human Values and Well-Being

Engineering the next generation of experimental physics

The scuba diving industry is funding marine ecosystem conservation and employing locals

BATMAN brings TCR therapy out of the shadows

Surrogates more likely to be diagnosed with mental illness, study finds

Columbia Engineering researchers turn dairy byproduct into tissue repair gel

Global estimates of lives and life-years saved by COVID-19 vaccination during 2020-2024

Potential trade-offs of proposed cuts to the NIH

New research simulates cancer cell behavior

COVID, over 2.5 million deaths prevented worldwide thanks to vaccines. One life saved for every 5,400 doses administered

Scuba diving generates up to $20 billion annually

Scientists advance efforts to create ‘virtual cell lab’ as testing ground for future research with live cells

How DNA packaging controls the “genome’s guardian”

Simplified models, deeper insights: Coarse-grained models unlock new potential for ionic liquid simulations

Gorillas’ personal circumstances shape their aggression towards groupmates

[Press-News.org] Novel drug regimen can improve stem cell transplantation outcomes
Bortezomib (Velcade) reduces GVHD, boosts survival